粤万年青(301111) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥70,812,585.48, a decrease of 0.54% compared to ¥71,196,522.47 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥3,441,732.40, representing a decline of 129.32% from a profit of ¥11,738,167.74 in the previous year[5] - The basic and diluted earnings per share were both -¥0.02, down 128.57% from ¥0.07 in the previous year[5] - The company reported a net profit attributable to shareholders of -3.44 million RMB, a decrease of 129.32% compared to the same period last year[17] - Operating revenue for the first quarter of 2025 was 70.81 million RMB, a slight decrease of 0.54% year-on-year[17] - The company reported a net profit of -4,103,207.13, compared to a net profit of 11,469,685.34 in the previous period, indicating a significant decline[25] - Operating profit was -3,285,979.26, down from 13,315,867.35 in the previous period, reflecting a substantial decrease in operational performance[25] - The company recorded a total profit of -3,224,388.91, compared to 13,523,137.86 in the previous period, indicating a significant drop in overall profitability[25] Cash Flow - The net cash flow from operating activities was -¥15,921,419.26, a significant decrease of 23,162.65% compared to -¥68,441.98 in the same period last year[5] - The net cash flow from operating activities was -15.92 million RMB, a significant decline of 23,162.65% due to ongoing investments in new business segments[13] - Cash flow from operating activities showed a net outflow of -15,921,419.26, compared to a much smaller outflow of -68,441.98 in the previous period[27] - The company's cash and cash equivalents decreased to CNY 104,933,304.35 from CNY 159,100,886.52[20] - Total cash and cash equivalents at the end of the period were 104,933,304.35, down from 159,100,886.52 at the beginning of the period[28] - The company’s cash flow from financing activities showed a net inflow of 3,780,503.08, compared to an outflow of -284,803.09 in the previous period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥920,505,782.32, a decrease of 1.36% from ¥933,166,569.41 at the end of the previous year[5] - The total assets of the company as of March 31, 2025, were CNY 920,505,782.32, down from CNY 933,166,569.41 at the beginning of the period[22] - The total liabilities decreased to CNY 154,394,324.06 from CNY 166,415,829.70[23] - The company's retained earnings decreased to CNY 159,732,407.59 from CNY 163,174,139.99[23] Investments and Acquisitions - The goodwill increased by 42.67% to ¥10,446,611.65 due to the acquisition of Hainan Wanmitang Pharmaceutical Co., Ltd.[11] - The company expanded its medical health business segment, leading to a 55.09% increase in other receivables to ¥4,169,836.54[11] - The company reported a 114.99% increase in trading financial assets to ¥74,847,626.64, primarily due to new financial products purchased during the period[9] - The company incurred non-recurring gains of ¥1,214,492.33 during the reporting period[7] - The acquisition of Hainan Wanmitang Pharmaceutical Co., Ltd. impacted profits by 11.06 million RMB, reflecting the costs associated with integrating new operations[17] - Hainan Wanmitang acquired 100% equity of Jiangxi Yuanqifud Pharmacy Chain Co., Ltd. and its 5 stores for CNY 500,000, enhancing its market presence through digital marketing strategies[19] - The company increased its investment in Noah Weikang by CNY 5.2 million, raising its ownership from 81% to 87.5%[19] Expenses - Management expenses increased by 61.07% to 12.67 million RMB due to the expansion into the healthcare and traditional Chinese medicine sectors[12] - Financial expenses rose by 154.43% to 0.24 million RMB, primarily due to increased financing costs from lease amortization[12] - Investment income decreased by 60.93% to 1.15 million RMB, attributed to reduced idle funds available for investment and lower financial market yields[12] - The company incurred a credit impairment loss of 135.42 thousand RMB, a decrease of 91.94% due to reduced bad debt write-offs[12] Sales and Market Performance - The company successfully won the national procurement for the product "Shengqi Jiangtang Pian," with a price reduction of approximately 30% compared to the original sales price, which is expected to expand sales in public hospitals and increase market share[18] - The registered capital of the subsidiary Hainan Wanmitang was increased from CNY 1 million to CNY 11 million, with the company holding a 51% stake post-increase[18] - The company received cash inflows from sales of 70,284,058.33, an increase from 67,764,781.90 in the previous period[27] Overall Financial Condition - The weighted average return on equity was -0.45%, down from 1.50% in the previous year[5] - The company's total comprehensive income attributable to the parent company was significantly lower, reflecting the overall decline in financial performance[26]